FXR agonists might therefore represent useful agents to reduce inflammation in cells with high FXR expression levels, such as hepatocytes, and to prevent or delay cirrhosis and cancer development in inflammation-driven liver diseases. This evidence concerns the gene NR1H4 and cancer.